Short Summary
The USPTO denied Cisco and Fortinet's request for Director review of a prior institution denial in IPR2024-00540, leaving the original decision unchanged.
Detailed Summary
In IPR2024-00540 concerning U.S. Patent 8,347,350, Cisco Systems and Fortinet petitioned for Director review of the USPTO's earlier decision to deny institution of an inter partes review against InfoExpress. Director Katherine K. Vidal recused herself, and Deputy Under Secretary Derrick Brent evaluated the request. The Director ultimately denied the review, affirming the original institution denial and concluding the petitioners' attempt to revive the IPR.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before local courts. Understanding the court's reasoning in CISCO SYSTEMS, INC. et al. vs InfoExpress Inc. is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
Cisco Systems, Inc.vsWSOU Investments LLC d/b/a Brazos Licensing and Development
Cisco Systems successfully petitioned the PTAB to institute an IPR against WSOU Investments regarding network protection claims (8982691). The Board found sufficient evidence of obviousness under 35 U.S.C. § 103, specifically finding that prior art references inherently disclose key claim limitations.
Intel Corporation et al.vsAdvanced Cluster Systems, Inc.
Intel and AMD have filed a joint motion to terminate IPR2025-00916 after reaching a settlement with patent owner Advanced Cluster Systems. The motion cites statutory authority and argues that termination conserves resources and supports settlement policy.
Ford Motor CompanyvsAutoConnect Holdings LLC
AutoConnect Holdings seeks Director review of a PTAB decision that granted institution based on Ford’s supplier‑based settled‑expectations argument. The patent owner contends the factual basis is unsupported and asks for denial of institution.
SAMSUNG ELECTRONICS CO., LTD., et al.vsSinotechnix LLC
Samsung Electronics has filed an IPR petition seeking to invalidate claims 1‑4 and 6 of Sinotechnix’s 9,412,913 LED‑package patent, asserting obviousness and anticipation based on five prior‑art references.
Sarepta Therapeutics, Inc. et al.vsGenzyme Corporation et al.
Sarepta filed an IPR petition seeking to invalidate Genzyme’s ’313 AAV detection patent. The petition asserts that all 27 claims are obvious in view of earlier publications on LC‑MS and RP‑HPLC analysis of viral proteins. No secondary considerations are believed to overcome the obviousness argument.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.